Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Baricitinib [1187594-09-7]
Cat# T2485-2mg
Size : 2mg
Brand : TargetMol
Baricitinib
Catalog No. T2485 CAS 1187594-09-7
Synonyms: INCB028050, LY3009104
Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities.
All TargetMol products are for research or drug registration purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose in violation of laws and regulations.
Baricitinib, CAS 1187594-09-7
| Description | Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. |
| Targets&IC50 | JAK2:5.7 nM, JAK1:5.9 nM, TYK2:53 nM, JAK3:>400 nM |
| In vitro | In adjuvant-induced arthritis rat models, Baricitinib (10 mg/kg orally) inhibits JAK1/2 signaling pathways and suppresses immune infiltration. In both CIA and CAIA models, Baricitinib (10 mg/kg) mitigates cartilage damage and inflammation and inhibits delayed-type hypersensitivity reactions. |
| In vivo | In immature T cells isolated from the peripheral blood (IC50=20 nM), Baricitinib inhibits the phosphorylation of STAT3 stimulated by IL-23. Additionally, in peripheral blood mononuclear cells, Baricitinib suppresses the phosphorylation of the STAT3 substrate induced by IL-6 (IC50=44 nM) and subsequently inhibits the production of the chemokine MCP-1 (IC50=40 nM). |
| Kinase Assay | Enzyme assays are performed using a homogeneous time-resolved fluorescence assay with recombinant epitope tagged kinase domains (JAK1, 837-1142; JAK2, 828-1132; JAK3, 718-1124; Tyk2, 873-1187) or full-length enzyme (cMET and Chk2) and peptide substrate. Each enzyme reaction is performed with or without test compound (11-point dilution), JAK, cMET, or Chk2 enzyme, 500 nM (100 nM for Chk2) peptide, ATP (at the Km specific for each kinase or 1 mM), and 2.0% DMSO in assay buffer. The calculated IC50 value is the compound concentration required for inhibition of 50% of the fluorescent signal. Additional kinase assays are performed at Cerep using standard conditions at 200 nM. Enzymes tested included: Abl, Akt1, AurA, AurB, CDC2, CDK2, CDK4, CHK2, c-kit, EGFR, EphB4, ERK1, ERK2, FLT-1, HER2, IGF1R, IKKα, IKKβ, JNK1, Lck, MEK1, p38α, p70S6K, PKA, PKCα, Src, and ZAP70[1]. |
| Cell Research | Baricitinib(INCB 028050) is dissolved in stock solutions, and then diluted with appropriate media before use[1]. Human PBMCs are isolated by leukapheresis followed by Ficoll-Hypaque centrifugation. For the determination of IL-6-induced MCP-1 production, PBMCs are plated at 3.3×105 cells per well in RPMI 1640+10% FCS in the presence or absence of various concentrations of INCB028050 (1 nM, 10 nM, 100 nM, 1 μM, and 10 μM). Following preincubation with compound for 10 min at room temperature, cells are stimulated by adding 10 ng/mL human recombinant IL-6 to each well. Cells are incubated for 48 h at 37°C, 5% CO2. Supernatants are harvested and analyzed by ELISA for levels of human MCP-1. The ability of INCB028050 to inhibit IL-6-induced secretion of MCP-1 is reported as the concentration required for 50% inhibition (IC50). Proliferation of Ba/F3-TEL-JAK3 cells is performed over 3 d using Cell-Titer Glo[1]. |
| Synonyms | INCB028050, LY3009104 |
| Molecular Weight | 371.42 |
| Formula | C16H17N7O2S |
| CAS No. | 1187594-09-7 |
Storage
Solubility Information
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 55 mg/mL (148.08 mM)
References and Literature
1. Fridman JS, et al. J Immunol, 2010, 184(9), 5298-5307. 2. Kontzias A, et al. Curr Opin Pharmacol, 2012, 12(4), 464-470. 3. Norman P, et al. Expert Opin Ther Pat, 2012, 22(10), 1233-1249. 4. Norman P, et al. Expert Opin Ther Pat, 2012, 22(9), 1105-1109. 5. Kvacskay P, Yao N, Schnotz J H, et al. Increase of aerobic glycolysis mediated by activated T helper cells drives synovial fibroblasts towards an inflammatory phenotype: new targets for therapy?[J]. Arthritis Research & Therapy. 2021, 23(1): 1-15.
Citations
1. Si H, Wang J, He R, et al. Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor. Frontiers in oncology. 2021, 11: 807200-807200. 2. Yao N, Tretter T, Kvacskay P, et al. Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes. Biomedicines. 2021, 9(10): 1413. 3. Luschnig P, Kienzl M, Roula D, et al. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Biochemical Pharmacology. 2021: 114690. 4. Kvacskay P, Yao N, Schnotz J H, et al. Increase of aerobic glycolysis mediated by activated T helper cells drives synovial fibroblasts towards an inflammatory phenotype: new targets for therapy. Arthritis Research & Therapy. 2021 Feb 15;23(1):56. doi: 10.1186/s13075-021-02437-7. 5. Kvacskay P, Yao N, Schnotz J H, et al. Increase of aerobic glycolysis mediated by activated T helper cells drives synovial fibroblasts towards an inflammatory phenotype: new targets for therapy?. Arthritis Research & Therapy. 2021, 23(1): 1-15.